• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:李文龙,姚尚辰,张玉,吴朝阳,魏京京,黄海伟,孙会敏.注册检验视角下我国境外生产化学药品的发展趋势分析[J].药学研究,2025,44(8):767-773[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1945次   下载 742次 本文二维码信息
码上扫一扫!
注册检验视角下我国境外生产化学药品的发展趋势分析
李文龙,姚尚辰,张玉,吴朝阳,魏京京,黄海伟,孙会敏
字体:加大+|默认|缩小-
(中国食品药品检定研究院,国家药品监督管理局化学药品质量研究与评价重点实验室,药品监管科学全国重点实验室,北京 102629)
摘要:
目的 为药品监管机构的政策制定和境内药品生产企业的研发生产提供参考。方法 梳理统计2015年至2023年境外生产化学药品注册检验的数据,从原料药和制剂的角度,结合发补检验情况,分析注册检验数量、品种、适应证、生产国、境内代理机构等信息的变化、原因和发展趋势。结果 我国境外生产化学药品注册检验数量以2018年为拐点呈现先降后升的变化趋势。原料药和制剂发补检验数量和占比从2020年开始逐年增加,发补检验项目最多的为有关物质。结论 监管政策的调整对原料药的注册检验量影响显著,进而影响注册检验总量。国内生产企业可从创新和鼓励仿制等多角度进行差异化竞争。监管部门可进一步强化对境外生产药品的上市后监管和核查监督,保障境外生产化学药品质量的安全性。药品注册申请人可结合国内外指导原则建立完善的质量标准,代理机构持续加强政策学习,提升注册检验材料质量,保障注册检验时效。
关键词:  境外生产化学药品  进口药品  原料药  注册检验  发补检验  监管科学
DOI:10.13506/j.cnki.jpr.2025.08.007
基金项目:中国食品药品检定研究院化学药品检定所学科建设课题(No.2023HYZX32);中国食品药品检定研究院中青年发展研究基金课题(No.2019G1)
出版日期:2025-08-25
Analysis of development trends in overseas produced of chemical drugs in China from the perspective of registration and inspection testing
LI Wenlong,YAO Shangchen,ZHANG Yu,WU Chaoyang,WEI Jingjing,HUANG Haiwei,SUN Huimin
(NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China)
Abstract:
Objective To provide reference for the policy formulation of drug regulatory agencies and the R&D and production of domestic drug manufacturers.Methods Combing and counting the data of registration inspection of overseas produced of chemical drugs in China from 2015 to 2023, we analyze the changes, reasons and development trend of the information of the number of registration inspections, varieties, indications, production countries, and agents in the territory from the perspectives of APIs and preparations, combined with the issuance of complementary inspections.Results The number of registration inspection of overseas produced of chemical drugs showed a trend of first decrease and then increase with 2018 as the inflection point.The number and proportion of APIs and preparations issued with supplementary inspection increased year by year from 2020, and the most items issued with supplementary inspection were related substances.Conclusion The adjustment of regulatory policies has a significant impact on the amount of registered tests of APIs, which in turn affects the total amount of registered tests.Domestic manufacturers could differentiate their competition from multiple perspectives such as innovation and encouraging imitation.Regulatory authorities could further strengthen the post-marketing regulation and verification supervision of overseas produced of chemical drugs to ensure the safety of the quality.Registration applicants could establish perfect quality standards by combining domestic and foreign guidelines, and agents could continuously strengthen policy learning, improve the quality of registration and inspection materials, and guarantee the timeliness of registration and inspection.
Key words:  Overseas production of chemical drugs  Import drugs  Active pharmaceutical ingredients  Registration testing  Issuance of replacement inspection  Regulatory science
今日访问量:2493    总访问量:55338936
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司